Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling

Eli Lilly became the first drugmaker to surpass a trillion-dollar valuation by driving revenue through mass market adoption rather than price increases.

MarketBeat

How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Barchart

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback. It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.

Barchart

3 Weight-Loss Drug Stocks To Consider For 2026

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Benzinga

Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain highly confident,...

Barchart

GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers

Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Fortune

This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs

Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year. Analyst sentiment is overwhelmingly positive, with most major firms rating LLY...

Barchart

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring

Something big is happening in healthcare, as pharma stocks have recently rallied on breakthrough AI developments that could reshape the entire industry.

Benzinga

UK officials ‘working day and night’ to resolve NHS drug pricing row’

Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition

The Guardian - UK

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing…

Benzinga

Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since

Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Kiplinger

Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know

Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and related conditions.

Benzinga

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Eli Lilly Co. (NYSE:LLY) is reportedly dropping CVS Health Inc.'s (NYSE:CVS) drug benefit plan for its employees.

Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. (NYSE:LLY), delivered a scathing critique of pharmacy benefit managers (PBMs), accusing the industry’s “middle actors” of “rent taking” and creating a “terrible incentive” structure that caused insulin list prices to skyrocket.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration

MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY).

Benzinga

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

The Independent UK

This next-gen weight-loss drug offers a new hope — and a bonus Ozempic and Wegovy don’t have

The once-weekly shot may be a tempting alternative to popular GLP-1 class drugs like Ozempic and Wegovy

The Independent UK

On the same day as his ‘fat jab’ launch, Trump issued new reason to deny visas to foreigners: obesity

The guidance describes obese foreigners as a ‘public charge’ and orders visa officers to guess how much they would claim in benefits

Benzinga

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program.

International Business Times

Trump Unveils 'TrumpRx' Program Slashing Prices of Wegovy and Zepbound

Trump launches "TrumpRx" program to cut prices of Wegovy and Zepbound, making weight-loss drugs more affordable for Americans.

Benzinga

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.